TDF单药治疗在中国慢性乙型肝炎患者中的先验核素（t）ide模

StephenW

Biomed Res Int. 2017;2017:2463197. doi: 10.1155/2017/2463197. Epub  2017 Apr 12.
TDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China.Huang M1, Lin G2, Shi H2, Wu Y2, Jie Y2, Zhu Z3, Chong Y2.
Author information
1Department of Infectious Diseases, The Fifth Affiliated Hospital of Sun Yat-sen University (SYSU), Zhuhai, Guangdong, China.2Department of Infectious Diseases, The Third Affiliated Hospital, Sun Yat-sen University (SYSU), Guangzhou, Guangdong, China.3Department of Stem Cell Biology and Regenerative Medicine, Cleveland Clinic, Lerner Research Institute, Cleveland, OH 44195, USA.

AbstractBACKGROUND/AIMS: Many patients had to transfer to tenofovir disoproxil fumarate (TDF) if there is other nucleos(t)ide analogue (NA) resistance. We aimed to investigate antiviral effects of TDF monotherapy between NA-naive and NA-experienced chronic hepatitis B (CHB) patients in China.
METHODS: A total of 102 NA-naive and NA-experienced CHB patients with TDF monotherapy (300 mg/day) were retrospectively analyzed for useful parameters up to 72 weeks.
RESULTS: There were 36 and 66 patients with matched HBV DNA baseline level in NA-naïve and NA-experienced group, respectively. There were no significant differences between NA-naïve and NA-experienced groups in HBV DNA levels (all P > 0.05) and HBV DNA undetectable rates (all P > 0.05) at all time points. At the end of follow-up, HBV DNA undetectable rates in NA-naïve and NA-experienced group were 96.2% (25/26) and 91.8% (45/49), respectively (P = 0.476). Baseline HBV DNA level was the only independent predictor for HBV DNA negative time (P = 0.018). In addition, 27.8% (5/18) and 11.4% (4/35) achieved HBeAg seroconversion at the end of the follow-up, respectively (P = 0.133).
CONCLUSIONS: TDF monotherapy was effective regardless of prior NA experienced. Baseline HBV DNA was a key predictive factor for HBV DNA negative time in TDF monotherapy.

StephenW

生物医学研究2017; 2017：2463197。 doi：10.1155 / 2017/2463197。 Epub 2017 Apr 12。
TDF单药治疗在中国慢性乙型肝炎患者中的先验核素（t）ide模拟治疗无效。
黄M1，林G2，施H2，吴Y2，杰Y2，朱Z3，崇Y2。
作者信息

1
    中山大学附属第三医院传染病科，中国广东珠海。
2
    中山大学中山大学第三附属医院传染病科。
3
    Department of Stem Cell Biology and Regenerative Medicine，Cleveland Clinic，Lerner Research Institute，Cleveland，OH 44195，USA。

抽象
背景/目的：

如果存在其他核仁（t）ide类似物（NA）抗性，许多患者必须转移到替诺福韦富地罗芬替莫西尔（TDF）。我们旨在调查中国NA-naive和NA经历的慢性乙型肝炎（CHB）患者之间TDF单一疗法的抗病毒作用。
方法：

共有102名NA-naive和NA经验的患有TDF单一疗法（300mg /天）的CHB患者进行回顾性分析72周的有用参数。
结果：

NA-na和NA经验组分别有36例和66例匹配的HBV DNA基线水平的患者。 HBV DNA水平（均P> 0.05）和HBV DNA检测率均无差异（均P> 0.05），差异无统计学意义（P> 0.05）。随访结束时，NA-NAI和NA组HBV DNA检出率分别为96.2％（25/26）和91.8％（45/49）（P = 0.476）。基线HBV DNA水平是HBV DNA阴性时间的唯一独立预测因子（P = 0.018）。另外27.8％（5/18）和11.4％（4/35）分别在随访结束时达到HBeAg血清学转换（P = 0.133）。
结论：

无论先前的NA经历，TDF单一疗法都是有效的。基线HBV DNA是TDF单药治疗HBV DNA阴性时间的关键预测因素。